Heart Failure
FDA approves first IV iron replacement therapy for heart failure
The FDA approved the first IV ferric carboxymaltose injection for iron deficiency in adults with heart failure to improve exercise capacity, according to a press release from American Regent.
AI models identify five distinct heart failure types, better predicting prognosis
Researchers have identified five distinct heart failure subtypes using machine learning methods across nationally representative datasets that may predict prognosis and ultimately guide treatment plans for patients.
Early, rapid uptitration of HF therapies after discharge reduces death, readmission risk
Rapid uptitration of medical therapy early after hospitalization for acute HF improves prognosis independent of left ventricular ejection fraction, according to a prespecified analysis of the STRONG-HF trial.
Use of pulmonary artery catheters beneficial in cardiogenic shock due to acute HF
In patients with cardiogenic shock due to acute heart failure, use of a pulmonary artery catheter was associated with reduced risk for in-hospital mortality, according to a retrospective observational study.
In nonischemic cardiomyopathy, women with CRT-D appear to have best outcomes: BIO-LIBRA
In patients with nonischemic cardiomyopathy, women had lower rates of ventricular arrhythmias and death than men, especially if they had a cardiac resynchronization therapy defibrillator, according to the results of the BIO-LIBRA study.
IMPLEMENT-HF
Comparing a virtual care team strategy with usual care for prescribing guideline-recommended HF therapies.
Heart failure hospitalization, mortality varies globally by national economic level
After adjusting for factors including use of long-term therapies, the risk for mortality within 30 days of first heart failure hospitalization was between three- and fivefold higher in lower-income vs. higher-income countries, data show.
Anemia before, after heart failure device implant common, driving poor survival
Data from a North American registry show anemia can affect more than 75% of candidates for a left ventricular device implant and up to 67% of recipients in the years after implant, driving higher mortality risk and worse quality of life.
FDA expands dapagliflozin indication to include all patients with HF
The FDA expanded an indication for the SGLT2 inhibitor dapagliflozin to reduce risk for CV death, HF hospitalization and urgent HF visits for adults with HF across the full range of ejection fraction, according to an industry press release.
Empagliflozin HF benefits extend across spectrum of kidney disease
Kidney disease does not influence the benefits of the SGLT2 inhibitor empagliflozin on major HF events, even in patients at high renal risk, according to a new analysis of the EMPEROR-Pooled study.